Home > Therapeutic areas > Oncology

PRESCRIPTION

Oncology
Name of the pharmaceutical product Active substance Summary product characteristics Patient information leaflet
Blastomat Temozolamide Reference Reference
Blastomat 100 mg Temozolamide Reference Reference
Blastomat 140 mg Temozolamide Reference Reference
Blastomat 20 mg Temozolamide Reference Reference
Litak 2 mg/ml – 5 ml Cladribine Reference Reference
Capecitabine Norameda Capecitabine Reference Reference
Capecitabine Norameda 150 mg Tab. N60 Capecitabine Reference Reference
Capecitabine Norameda 500 mg Tab. N120 Capecitabine Reference Reference
Docetaxel Docetaxel Reference Reference
Docetaxel Hospira 10 mg/ml Docetaxel Reference Reference
Docetaxel Teva Pharma 20 mg/ml Docetaxel Reference Reference
Glipox Imatinib Reference Reference
Glipox 400 mg Imatinib Reference Reference
Varlota Erlotinib Reference Reference
Varlota 100 mg Tab. N30 Erlotinib Reference Reference
Varlota 150 mg Tab. N30 Erlotinib Reference Reference
Inflectra 100 mg Infliximab Reference Reference
Topotecan Hospira 4 mg/4 ml Topotecan Reference Reference
Sangrel 1 mg – 5 ml N1 Bortezomib Reference Reference
Thromboreductin 0,5 mg Tab. N100 Anagrelide Reference Reference
Reseligo 3,6 mg Goserelin Reference Reference
Algonad 10,8 mg Goserelin Reference Reference
Exemestane 25 mg Tab. N30 Exemestane Reference Reference
Nivestim Filgrastim Reference Reference
Nivestim 48 MV/0,5 ml Filgrastim Reference Reference
Nivestim 30 MV/0,5 ml Filgrastim Reference Reference
Remurel Glatiramer acetate Reference Reference
Remurel 20mg/ml inj tirp švir 1ml N28 Glatiramer acetate Reference Reference
Remurel 40mg/ml inj tirp švir 1ml N28 Glatiramer acetate Reference Reference